New device for treating hemorrhoids
Official title: SCI-Pex, a Multi-center, Prospective, Non-controlled Investigation to Evaluate the Safety and Performance of PexyEazy®, a Device for Treatment of Hemorrhoids
Run by Developeration AB · NCT05782010 · Data updated 2026-11-12
This study is testing a new device called PexyEazy® to see if it can safely and effectively treat grade II and III hemorrhoids in patients while making recovery easier and faster.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 84 Years |
| Sex | All |
| Enrollment | 35 (estimated) |
| Sponsor | Developeration AB Industry-sponsored |
| Drugs / interventions | radiation |
| Locations | 3 sites (Frölunda and 2 other locations) |
| Status | Recruiting |
| Started | June 15, 2023 |
| Main results expected | April 28, 2026 |
| Study ends | May 30, 2026 |
| Registry record updated | March 7, 2025 |
| Trial ID | NCT05782010 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with grade II and III hemorrhoidal disease who are classified as ASA I-III.
✕Probably not a fit
Patients with a history of recent surgical treatments for hemorrhoids or those with certain gastrointestinal diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The SCI-Pex study evaluates the safety and performance of PexyEazy®, a semi-automatic device designed for the treatment of grade II and III hemorrhoids using the mucopexy method. This multicenter, prospective investigation involves 35 patients and aims to assess outcomes such as adverse events, pain levels, and quality of life through questionnaires and clinical examinations at various follow-up intervals. The procedure is performed on awake patients in under 10 minutes, potentially reducing recovery time compared to traditional surgical methods.
Why it matters
Potential benefit: If successful, this device could provide a quicker, less painful treatment option for patients suffering from hemorrhoids.
How similar studies have gone: While traditional mucopexy methods have shown success, the semi-automatic approach of PexyEazy® is a novel intervention that has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult * Hemorrhoidal disease grade II and III * American Society of Anesthesiologists (ASA) classification I-III. Exclusion Criteria: * Previous surgical treatment for hemorrhoids by all methods except rubber band ligation or sclerosing injection therapy within the last 3 years. * Previous surgical treatment with rubber band ligation or injection therapy within the last 2 months. * More than three surgical treatments with rubber band ligation or sclerosing injection therapy within the last 3 years. * Under medication with immunosuppressive drugs and/or anticoagulant drugs (not including 75mg acetylsalicylic acid) and not able to interrupt the anticoagulant drug medication or replace it with low molecular weight heparin for 5 days. * Have ulcerative colitis, Crohn's disease or other intestinal inflammatory disease or presence of inflamed or thickened mucosa of the rectum. * Presence of anal fissure, anal stenosis, stricture, fistulas or ulcers in the rectal area. * The rectum has not been prepared prior to the investigation with rectal enema and is contaminated with feces that cannot easily be removed. * Have schizophrenia, untreated depression or other mental illness or conditions that may affect judgment, sensation of pain or inability to complete the follow-up. * Under medication of morphine or other strong painkillers, not including paracetamol. * Fecal incontinence (not including soiling due to hemorrhoidal disease), or conditions with impaired sensation in the rectal area or impaired function of the anal sphincter. * Previous rectal radiation. * Rectal cancer or previous surgery due to rectal cancer. * Pregnancy * Hypercoagulability disorders or diseases that result in increased risk of bleeding. * Impaired immune system or condition that increases the risk of infection.
Where it's running
-
Frölunda Specialistsjukhus
Frölunda, Sweden Recruiting -
Norrtälje Sjukhus
Norrtälje, Sweden Recruiting -
Capio kirurgkliniken, Sophiahemmet
Stockholm, Sweden Not yet recruiting
Study contacts
- Principal investigator: Ulf Kressner, Dr — Norrtälje Sjukhus
- Study coordinator: Johan Ungerstedt, Dr
- Email: johan.ungerstedt@developeration.se
- Phone: +46709427842
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Signia circular stapler for left-sided colon, sigmoid, and rectal resections
This study will try the Signia circular stapler with Tri-Staple technology to see if it safely creates bowel reconnections in adults having left-sided colon, sigmoid, or rectal surgery.
-
PF-08634404 plus chemotherapy for adults with metastatic colorectal cancer
This trial will test whether adding a new drug called PF-08634404 to standard chemotherapy helps adults whose colorectal cancer has spread.
-
Ligasure vs. Conventional Diathermy in Hemorrhoidectomy
This study tests whether using the Ligasure device during hemorrhoidectomy reduces pain and bleeding compared with conventional diathermy in patients with symptomatic hemorrhoids.
-
Sutureless hemorrhoidectomy vs conventional ligation for advanced hemorrhoids
This study tests whether a sutureless, energy-based hemorrhoidectomy can reduce pain and recovery time compared with the standard Milligan-Morgans procedure in adults with Grade III–IV hemorrhoids.
-
Hemorrhoidal artery embolization versus rubber band ligation for internal hemorrhoid bleeding
This trial will test whether hemorrhoidal artery embolization or rubber band ligation better stops bleeding and improves symptoms in adults with internal hemorrhoids.
-
Microbiome in esophageal and stomach leaks
This project will test whether microbes in leaked fluid and nearby tissue from adults with esophageal or stomach leaks differ in ways that affect healing and complications.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.